{"id":"W4388589580","doi":"10.1093/neuonc/noad179.0366","title":"CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Regorafenib; Medicine; Clinical endpoint; Randomization; Randomized controlled trial; Internal medicine; Oncology; Hazard ratio; Confidence interval; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001591366,0.001061588,0.001222418,0.0003013084,0.0003085498,0.001021977,0.0005208811,0.0007884616,0.007182708],"category_scores_gemma":[0.002249789,0.0002946842,0.001447815,0.000292673,0.0005835409,0.0008164894,0.0003364907,0.002514833,0.001283393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354264,"about_ca_system_score_gemma":0.001461628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001892377,"about_ca_topic_score_gemma":0.005388205,"domain_scores_codex":[0.9994168,0.0003137705,0.00002163679,0.00009943721,0.00008344181,0.00006495741],"domain_scores_gemma":[0.9994177,0.0001188255,0.0001450028,0.00007175299,0.0000548293,0.000191928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7755191,0.005371389,0.002998228,0.002605275,0.003551596,0.00009999523,0.0001498596,0.004143164,0.007145602,0.002025298,0.04158663,0.1548038],"study_design_scores_gemma":[0.8343775,0.103796,0.01462322,0.0006487299,0.003652168,0.0003631331,0.0000843865,0.005222785,0.003310356,0.002876883,0.03095952,0.00008532205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8986216,0.02844627,0.00407814,0.004921711,0.001391265,0.004771798,0.01734055,0.0009612541,0.03946747],"genre_scores_gemma":[0.9538503,0.005382427,0.004211268,0.0031891,0.0005246494,0.003747116,0.0146371,0.0001559559,0.01430215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007182708,"threshold_uncertainty_score":0.0240286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3845344680919263,"score_gpt":0.455586521230215,"score_spread":0.07105205313828872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}